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SwitzerlandThe pathophysiologic side effects of cardiopulmonary
bypass have already been identified. Minimally invasive
extracorporeal circulation technologies (MiECT) and off-
pump coronary artery bypass graft surgery (OPCABG)
aim to reduce these problems. This meta-analysis pro-
vides a comparison of MiECT and OPCABG in random-
ized and observational studies. A fully probabilistic,
Bayesian approach of primary and secondary endpoints
was conducted. MiECT does not give inferior results*Drs Winkler and Heinisch contributed equally to this work.
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Switzerland; email: ppheinisch@googlemail.com.when compared with OPCABG. However, there is a trend
to borderline significantly higher blood loss in this group
in randomized controlled trials. The question whether
MiECT is equivalent to OPCABG can be answered with
the affirmative, but long-term follow-up data are needed
to detect any advantage over time.he technique of off-pump coronary artery bypassTgrafting (OPCABG) was established more than 3 de-
cades ago with the objective to reduce the unfavorable
pathophysiologic side effects of conventional cardiopul-
monary bypass circuits on the organ systems triggered by
complement system activation through foreign surfaces,
priming volume, and negative and positive pressures in
the reservoir [1, 2]. To overcome these effects, the concept
of minimally invasive extracorporeal circuits evolved over
the last 15 years not only as an alternative to the more
conventional extracorporeal circulation circuits but also
as an alternative to an off-pump strategy in case of cor-
onary artery bypass graft surgery (CABG) [3, 4]. The use
of minimally invasive extracorporeal circulation technol-
ogies (MiECT) is now expanding; these systems offer
several potential advantages because they reduce the
systemic inflammatory response and subsequent organ
dysfunction [5, 6].
The typical MiECT consists of a closed circuit, which
includes the oxygenator and the pump. The circuit has no
open venous reservoir. All components of the minimally
invasive extracorporeal circuits are coated with heparin,
and the tubing system is significantly reduced in length.
These characteristics permit a reduction of the priming
volume between 200 mL and 650 mL compared with the
standard extracorporeal circuit [3, 7]. The OPCABGtechnique has shown good results as postoperative
morbidity and mortality were reduced in various studies
compared with CABG with conventional circuits. But the
literature also presents some major drawbacks, such as a
higher rate of incomplete revascularization, especially in
dilated and hypokinetic hearts, due to more difficult
exposure of obtuse coronary marginal branches and the
lesser quality of the coronary anastomoses. For these
reasons, the initial enthusiasm for OPCABG has vanished
over the last years [8, 9]. Now, MiECT aims to incorporate
the advantages of a traditional cardiopulmonary bypass
circuit while overcoming the limitations of OPCABG [10].
With this is in mind, the main questions are these: (1) is
MiECT is comparable to OPCABG in terms of operative
outcomes; and (2) is the safety of a minimized heart-lung
machine (with less systemic inflammatory response) even
superior to OPCABG? The aim of the present meta-
analysis is to overcome the low power of the limited
sample sizes of the existing studies by pooling data of
3,410 patients, and to determine whether MiECT is a valid
or superior alternative to OPCABG [11].
To minimize selection bias, we decided to include all
studies that compare the two strategies, no matter
whether the design was randomized or not. Of course,
Abbreviations and Acronyms
AF = atrial fibrillation
CABG = coronary artery bypass graft surgery
CI = confidence interval
ICU = intensive care unit
MI = myocardial infarction
MiECT = minimally invasive extracorporeal
circulation technologies
OPCABG = off-pump coronary artery bypass
grafting
OR = odds ratio
RCT = randomized clinical trial
SMD = standardized mean difference
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research because they provide the strongest evidence of
treatment safety and efficacy. With respect to the com-
parison of MiECT versus OPCABG, randomized trials are
not very common, and those trials tend to include only
few patients [12]. Observational studies may provide
particularly relevant information on the topic; that is the
reason we decided to include observational studies. As
that might considerably increase heterogeneity, we
calculated all pooled estimates stratified by study design:
randomized versus observational.Material and Methods
Studies
The studies reviewed were randomized controlled trials
(RCT) and observational studies that compared OPCABG
and MiECT for patients undergoing CABG.
Participants
The studies reviewed involved adult patients (aged 18
years or more) who were undergoing cardiac surgery for
coronary artery disease with either OPCABG or MiECT.
Search Strategy and Data Source
The search for literature was performed through
PubMed, PubMed Central, Web of Science (includes
MEDLINE, Conference Proceedings Citation Index, Data
Citation Index CAB abstracts, Derwent Innovations
Index), OvidSP (includes EMBASE, Ovid MEDLINE,
HMIC, Transport Database). For the identification of
RCT, the Cochrane Library was accessed. In addition, we
searched Google scholar.
The searches were last updated on October 29, 2015.
The search terms used for minimal extracorporeal circu-
lation were “MECC” or “mini ECC” or “MiECT” or
“minimal extracorporeal circulation” or “minimized
extracorporeal circulation” or “mini-extracorporeal
circulation” or “miniaturized extracorporeal circulation”
or “minimal extracorporeal circulation technique” or
“miniaturized extracorporeal circulation technique” or
“miniaturized ECC” or “miniaturized extracorporealcirculation circuit” or “minimal extracorporeal circulation
circuit.”
There are no defined Medical Subject Headings
(MeSH) terms for minimal extracorporeal circulation. The
MeSH term for off-pump coronary artery bypass grafting
was defined as “coronary artery bypass, off-pump,” or
search terms were used: “off-pump surgery” or “off-
pump CABG” or “off-pump coronary artery bypass
grafting” or “off-pump technology” or “off-pump coro-
nary revascularization” or “off-pump coronary artery
revascularization” or “off-pump coronary artery grafting”
or “off-pump revascularization technology” or “off-pump
coronary artery revascularization technique” or “off-
pump technique” or “off-pump CABG method” or
“OPCAB.”
No restrictions on publication status, time, or pre-
defined outcome were applied. Reference lists of evalu-
able studies, systematic reviews, meta-analyses, narrative
reviews, and reports were also hand searched for addi-
tional studies eligible for inclusion. The search was con-
ducted in compliance with the established Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) in health care interventions state-
ment (Appendix 1) [13].
Eligibility Criteria
Two authors independently screened all titles and
abstracts of the initial search, and reviewed full-text
articles with respect to eligibility for inclusion. Disagree-
ments were resolved by a third reviewer. The final deci-
sion was made on the basis of the full texts (Table 1).
Data Extraction and Analyses
Two authors (H.P.P. and B.G.) independently extracted
the data into a predefined scheme; disagreement was
solved by consensus, and the final decision was made by
a third author (B.W.). In addition to the extraction of
patient characteristics and operation details, we assessed
details of the methodology, the specific study question,
and inclusion criteria.
Study Design
Inhouse mortality was defined as the primary endpoint
for this analysis; secondary endpoints were stroke,
myocardial infarction (MI), postoperative atrial fibrilla-
tion (AF), total blood loss in milliliters, length of intensive
care unit (ICU) stay in hours and length of hospital stay in
days. We treated the number of anastomoses like an
endpoint to use the technique of random effects analysis.
Statistical Analysis
We conducted a fully probabilistic, Bayesian analysis
when events were rare, with mortality as a primary
endpoint and MI and stroke as secondary endpoints. We
used a Bayesian method developed for random effects
meta-analysis on the odds ratio (OR) scale [14, 15].
Further details can be found in Appendix 2.
The model adequately accounts for situations with
sparse event data, including zero cells in one or both
treatment group and control group. Monte-Carlo Markov
Table 1. Study Overview With All Included Studies
Study
Year of
Publication
Study
Design
Sample Size, n Mean Age, years
MiECTMiECT OPCABG MiECT OPCABG
Formica 2009 RCT 30 30 61.2  10.4 70  7.7 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
Formica 2013 RCT 20 20 69.9  8.7 70.8  7.0 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
Murakami 2005 RCT 7 8 62.8  6.0 70.2  1.7 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
Mazzei 2007 RCT 150 150 65.7  10.8 66.4  9.8 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
van Boven 2013 RCT 20 20 73.6  3.6 73.8  2.6 Rotaflow centrifugal pump and Quadrox
membrane oxygenator; Maquet GmbH
Wittwer 2011 RCT 42 34 65.6  11.2 64.7  10.9 ROCSafe systems; Terumo Medical Corp,
Somerset, NJ
Wittwer 2013 RCT 76 44 65.8  11.2 65.2  10.4 ROCSafe systems; Terumo Medical Corp,
Somerset, NJ
Reuthebuch 2014 Observational 555 42 65.01  9.5 69.39  9.5 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
Rosato 2012 Observational 50 50 64.1  9.6 65.6  12.3 Rotaflow centrifugal pump and Quadrox
membrane oxygenator; Maquet GmbH
Munos 2011 Observational 51 57 74.9  7.5 73.7  9.9 Rotaflow centrifugal pump and Quadrox
membrane oxygenator; Maquet GmbH
Panday 2009 Observational 220 109 66  11 64  11 Rotaflow centrifugal pump and Quadrox
membrane oxygenator; Maquet GmbH
Puehler 2009 Observational 558 558 67.5  8.8 66.8  9.5 Rotaflow centrifugal pump and Quadrox
membrane oxygenator; Maquet GmbH
Gerritsen 2006 Observational 93 95 68.3  8.8 67.5  9.6 Jostra MiECT system; Maquet-Jostra AG,
Hirrlingen, Germany
Reber 2010 Observational 117 185 72.1  8 69.3  1 St€ockert; Sorin Group, Munich,Germany, in
combination with ECCO perfusion system
Wippermann 2005 Observational 10 10 59.6  8.3 54.3  14.1 CORx; CardioVention, Santa Clara, CA
MiECT ¼ minimally invasive extracorporeal circulation technologies; OPCABG ¼ off-pump coronary artery bypass graft surgery;
RCT ¼ randomized clinical trial.
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distributions of the ORs of outcomes of interest and of
random-effects SD (s). For the control groups (OPCABG)
of each study, we set vague priors on the log of the odds
of the event risk using normal distribution centered at
zero with variance of 100.
For SD of random effects (s), we set an informative
prior, a half-normal distribution with a mean of 0.5
(further details available in Appendix 2). The 95%
credibility intervals were obtained from the 2.5th and
97.5th percentile of the posterior distribution, which
can be interpreted similarly to a conventional 95%
confidence interval (CI). We conducted the analysis
separately for randomized trials and observational
studies.
All other analyses have been done using STATA 12
software (StataCorp, College Station, TX). For the
binary outcomes, we calculated risk ratio and CI with a
continuity correction of 0.001 for all outcomes that we
observe zero in one arm or in both arms. With respect
to the primary outcome mortality, we used these risk
ratios as a sensitivity analysis for the Bayesian analysis
of rare events outcomes. For continuous outcomes, wecalculated standardized mean difference with CI be-
tween the treatments. We assessed heterogeneity by
calculating the I2 summary statistics. We follow Higgins
and colleagues [16] in quantifying heterogeneity by I2
into low (25%), moderate (50%), and high (75%).
As an approximation, we calculated SD of SE and
calculated the raw numbers of percent when investigators
reported only SE.
We calculated hours from days for the ICU stay if days
were reported. When only the median was given, we
included the median as a mean and approximated the SD
by using the mean of all reported SDs. We calculated a
separate sensitivity analysis to control for a bias induced
by these approximations.
The included papers reported blood loss within
different observation periods. We analyzed blood loss in
strata for 12 hours, 24 hours, 48 hours, and for the com-
plete postoperative period. For blood loss, we had to
construct the SD for one paper, and we constructed it
according to the stratum. We assessed publication bias
with respect to mortality by visual inspection of the fun-
nel plot and using Harbord’s modified test. All p values
and 95% CI are two sided.
Fig 1. Study selection overview.
Fig 2. Funnel plot showing no publication bias. (Black dots ¼ studies;
long-dash line¼ 1%; medium-dash line¼ 5%; short-dash line¼ 10%.)
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Results of Search
ELIGIBLE PAPERS. Overall, 204 publications were found that
potentially addressed the study question, of which 17
articles described a comparison of MiECT versus
OPCABG (Fig 1). Overall seven randomized controlled
(RCT) and eight observational studies were found
[5, 17–31]. After thorough review process, three publica-
tions were identified that were possibly based on the
same patient cohort. Therefore, two publications were
excluded [32, 33]. Furthermore, the quality of the included
studies were analyzed with respect to the comparability
and reported endpoints (Supplemental Table 1).
PUBLICATION BIAS. The funnel plot indicates that there is no
publication bias with respect to the primary endpoint,
which is confirmed by the Harbord test that yields overall
p ¼ 0.331, in randomized trials p ¼ 0.669, and in obser-
vational studies p ¼ 0.496 (Fig 2).
Estimates of Endpoints
ALL-CAUSE MORTALITY. Inhospital death is a rare outcome: 5
of 7 studies (71%) report zero events in both arms;
therefore, was analyzed using the Bayesian approach(Table 2). In the RCTs, the Bayesian OR is 0.64 with
credibility interval of 0.16 to 2.48; the corresponding fre-
quentist analysis yields an OR of 0.66 with CI 0.11 to 3.90.
In observational studies, the Bayesian OR is 0.76 with
credibility interval of 0.39 to 1.41; the frequentist OR is
Table 2. Combined Effect Sizes of Binary Endpoints
Variable
OR of MiECT Compared
With OPCABG
Randomized Observational
Mortality 0.64 (0.16–2.48)a 0.76 (0.39–1.41)a
Myocardial infarction . 1.15 (0.30–4.37)a
Stroke 2.1 (0.42–11.19)a 1.55 (0.68–3.37)a
Renal failure . 0.72 (0.38–1.38)
Postoperative AF 0.95 (0.71–1.26) 0.56 (0.45–0.69)
a Calculated using the Bayesian approach.
AF ¼ atrial fibrillation; MiECT ¼ minimally invasive extracorporeal
circulation technologies; OPCABG ¼ off-pump coronary artery
bypass graft surgery; OR ¼ odds ratio.
Published in final edited form as: Ann Thorac Surg. 2017 Jan;103(1):342-350. doi: 10.1016/j.athoracsur.2016.08.0670.77 with CI 0.48 to 1.25. In general, observational studies
report a higher mortality rate, but this difference does not
substantially affect the ORs, indicating that the difference
is the same in both treatment groups. No heterogeneity is
observed with respect to mortality (I2 ¼ 0), neither in the
RCTs nor in the observational studies, nor when both
types are considered together.
MYOCARDIAL INFARCTION. Myocardial infarction is a rare
event, it was not reported in any RCT; therefore, no effect
size can be calculated (Table 2). In observational studies,
MI is equally frequent after MiECT and OPCABG; the
Bayesian OR is 1.15 with credibility interval 0.3 to 4.37,
and the frequentist OR in observational studies is 2.22
with CI 0.43 to 11.61 with no heterogeneity (I2 ¼ 0).
STROKE. Stroke is a rare event: 36% of the studies report
zero events (Table 2). The stroke rate might be higher
after MiECT in RCTs, but the difference does not reach
significance. The Bayesian OR is 2.1 with credibility in-
terval 0.42 to 11.19. The corresponding frequentist OR
cannot be calculated (CI: 0 toN). In observational studies,
the Bayesian OR is 1.55 with credibility interval 0.68 to
3.37, which is close to the frequentist OR of 1.66, CI 0.83 to
3.33. No heterogeneity is observed in any group (I2 ¼ 0).
POSTOPERATIVE ATRIAL FIBRILLATION. With respect to AF,
there was no study reporting a rate of zero, so AF cannot
be considered as a rare event (Supplemental Fig 1). For
this reason, we analyzed it using the frequentist approach
(Table 2). Atrial fibrillation is equally frequent after
MiECT and after OPCABG, OR 0.87 (CI: 0.56 to 1.36) with
a high heterogeneity (81.1%), when all studies are
considered. In RCTs, the OR is 0.95 (CI: 0.71 to 1.26) with
no heterogeneity, whereas in observational studies, the
OR decreases to 0.56 (CI: 0.45 to 0.69) with high hetero-
geneity (90.3%).
RENAL DYSFUNCTION. Not a single case of acute kidney
injury was reported after MiECT in RCTs, so no effect size
can be calculated (Table 2). In observational studies, renal
failure is no rare event; the frequentist OR is 0.86, CI 0.34
to 2.16 with moderate heterogeneity (44.5%).
NUMBER OF ANASTOMOSES. The standardized mean differ-
ence (SMD) of the number of anastomoses is 0.82, CI 0.44
to 1.20 (the crude difference between the groups is 0.61,
CI: 0.56 to 0.66), but the heterogeneity between the trialsis very high (I2 ¼ 95%). In the RCTs alone, this difference
is smaller (0.56, CI: 0.39 to 0.72); and in the observational
studies, the difference is larger (1.12, CI: 1.03 to 1.21). In
both subgroups, heterogeneity is very high: I2 ¼ 91%
within the randomized trials; I2 ¼ 96% within the obser-
vational studies (Fig 3).
BLOOD LOSS. The SMD of blood loss is overall 0.16
(CI: 0.05 to 0.37), but with a high heterogeneity of 62%;
that comes exclusively from the observational studies
(I2 ¼ 0% within the RCTs and I2 ¼ 83.4% in observational
studies; Fig 4). In RCTs, the SMD is 0.23 (CI: 0.00 to 0.45),
whereas in observational studies, the SMD is 0.14
(CI: 0.21 to 0.50).
INTUBATION TIME, LENGTH OF ICU STAY, LENGTH OF HOSPITAL
STAY. Intubation time, length of ICU stay, and length of
hospital stay were similar in the two treatment groups
when considering all studies (0.07, CI: 0.21 to 0.35; 0.08,
CI: 0.04 to 0.21; and 0.04, CI: 0.25 to 0.32, respectively);
the RCTs (0.01, CI: 0.34 to 0.37; 0.11, CI: 0.11 to 0.32,
and 0.04, CI: -0.24 to 0.15, respectively); and in obser-
vational studies (0.22, CI: 0.16 to 0.6). However, only
Munos and associates [30] reported intubation time, 0.02
(CI: 0.08 to 0.12) and 0.69 (CI: 0.17 to 1.56). Heteroge-
neity is moderate for intubation time (I2 ¼ 51.1%, 59.6% in
RCTs and I2 not calculated in observational studies), low
for ICU stay (I2 ¼ 27.1%, with I2 ¼ 32.5% in RCTs and
I2 ¼ 0% in observational studies [Supplemental Fig 2]),
and high for hospital stay (overall I2 ¼ 77.6%, in RCTs
I2 ¼ 10.5% and in observational studies I2 ¼ 91.8%
[Supplemental Fig 3]).Comment
The concepts of MiECT and OPCABG have been intro-
duced in the field of CABG to eliminate or at least miti-
gate the disadvantages of standard extracorporeal
circulation [11, 34, 35]. Both methods have strengths and
benefits—for instance, the safety of a heart-lung machine
during the procedure but also the advantage of a “no
touch method” in OPCABG where the aorta is untouched
during cannulation and avoided for proximal anastomo-
ses [36–38]. These positive aspects compared favorably
with those after full extracorporeal circulation and have
been investigated in various studies over the past decade
[21, 39–41]. Nevertheless, different independent and sys-
tematic concerns have been raised with regard to both
applications [11]. The principal points of discussion are
perioperative outcome, safety of MiECT, and related
aspects, for example, aortic cannulation, filled heart,
impaired luxation, and volume shift, and conversely, the
known issues of OPCABG in terms of blood-free field
with related anastomosis quality, long-term patency, and
hemodynamic instability, as well as learning curve of the
surgeon and the anesthesiologist concerning intra-
operative management.
In this analysis, we were able that to demonstrate that
there is no disadvantage for MiECT when compared with
OPCABG, with respect to inhouse mortality, even though
blood loss is higher in MiECT patients, which we would
Fig 3. Number of anastomoses. (CI ¼ confidence interval; DþL Subtotal/Overall ¼ random effect meta-analysis; I-V Subtotal/Overall ¼ fixed
effects meta-analysis; MiECT ¼ minimally invasive extracorporeal circulation technologies; OPCAB ¼ off-pump coronary artery bypass; RCT ¼
randomized clinical trial; SMD ¼ standardized mean difference.)
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evidence that AF—a well-known factor for several related
comorbidities, for example, stroke, thromboembolisms
[42]—is more frequent after MiECT than after OPCABG,
neither in randomized nor in observational studies. The
number of anastomoses varies greatly between the studies
but is generally higher when MiECT is used, not only on
average but also for each of the included papers. The dif-
ference is smaller in RCTs, which could indicate that in a
randomized trial, surgeons tend to do an equal number of
grafts with MiECT and OPCABG (Fig 3).
One paper reported a follow-up longer than discharge
[28], but no paper reported long-term survival estimates
or hazard ratios for the two treatments. Long-term mor-
tality would be the most important outcome to reliably
compare the two strategies, because it is only in the long
term that advantages and disadvantages might or might
not compensate.
In randomized trials [5, 18–21, 31], the mortality rate
is biased: 2,760 of the 3,410 patients and 72 of the 78
inhouse deaths were extracted from observationalstudies. This bias, fortunately, does not induce a bias of
the ORs.
The risk of stroke is a significant issue for MiECT and
result (most frequently) from the cannulation of the
ascending aorta, especially when compared with the no-
touch technique of OBCABG [43]. Except for AF and
renal dysfunction, all binary endpoints are rare, so some
of the CIs are huge. Larger cohorts would increase the
reliability to the results. Blood loss is slightly more pro-
nounced in MiECT operations; the difference is larger in
randomized trials, indicating that in similar patients,
bleeding is more likely when MiECT is used.
The Bayesian method was chosen for the analysis of
rare endpoints (the primary endpoint mortality and the
secondary endpoints MI and stroke) because many
studies reported no event in one or both study arms
owing to small study sizes and rare endpoints. The usual
frequentist type of analysis cannot deal with zero cells
when calculating risk ratios; therefore, studies with empty
cells are omitted from the analysis or zero events are
replaced by partial events, the standard is 0.5. We
Fig 4. Blood loss. (CI ¼ confidence interval; DþL Subtotal/Overall ¼ random effect meta-analysis; I-V Subtotal/Overall ¼ fixed effects meta-
analysis; MiECT ¼ minimally invasive extracorporeal circulation technologies; OPCAB ¼ off-pump coronary artery bypass; RCT ¼ randomized
clinical trial; SMD ¼ standardized mean difference.)
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with either usual analysis strategy to be too high and so
decided to use the Bayesian method, which can handle
zero cells.
There are several limitations to this study. Most
important, to validly answer the question whether
MiECT might indeed be superior to OPCABG would
need long-term follow-up data. The advantages of either
treatment might prevail over time. Our study shares this
limitation with all other papers in the field. Most studies
do not report troponin, creatine kinase, and creatine
kinase–myocardial band, or not in a way that would be
comparable (time interval after surgery, measurement
regimen), which could be an excellent marker of cell
damage in the myocardium shortly after the operation
[44, 45]. A further limitation is that the included studies
do not give explicit definitions of MI or renal failure.
Furthermore, the differences among the techniques used
in MiECT or OPCABG are not reported for the included
studies, especially no separate event rates for different
MiECT or OPCABG strategies are provided in the
studies. Meta-analysis techniques have been developed
for RCTs, and inclusion of observational studies
increases the heterogeneity and widens the CIs of allestimates. Even so, we consider the analysis of obser-
vational studies justified by our results because, in this
case, far more statistical power was generated and pre-
dictions significantly enabled as stated above for each
endpoint. Future research should report long-term
follow-up and hazard ratios for the treatments with
respect to mortality.
In conclusion, using a meta-analytic approach
including randomized and observational studies, the
question whether MiECT is superior to OPCABG can
only be answered by long-term follow-up data. Including
all eligible studies, there is no short-term disadvantage of
MiECT compared with OPCABG in terms of MI, stroke,
AF, renal dysfunction, intubation time, length of ICU stay,
and inhouse mortality, even though blood loss is signifi-
cantly higher in the MiECT group in the RCTs. The
number of anastomoses is higher when MiECT is used,
not only on average but also for each of the included
papers. Minimally invasive extracorporeal circulation
technology can be considered a valid alternative to
OPCABG, especially when the support of a heart-lung
machine is mandatory. As advantages of MiECT might
prevail over time, however, long-term follow-up data and
large cohort studies are needed.
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